Literature DB >> 30603346

Different effects of linagliptin and sitagliptin on blood pressure and renal function in Japanese patients with type 2 diabetes mellitus.

Masayuki Tojikubo1, Yuji Tajiri2.   

Abstract

AIMS: To compare and evaluate effects of two DPP-4 inhibitors with different excretion routes on systemic and renal hemodynamics in Japanese patients with type 2 diabetes mellitus.
METHODS: Seventy-three outpatients with type 2 diabetes who had been treated by 50 mg/day of sitagliptin (S) for at least 1 year were enrolled and prescribed 5 mg/day of linagliptin (L) instead of S for the next 1 year.
RESULTS: After the initiation of S, the systolic and diastolic blood pressure decreased significantly. However, after switching to L for 1 year they increased significantly and returned to a comparable level as those before S treatment. The increase in serum creatinine or uric acid levels and the decrease in eGFR after S initiation were completely stopped or reversed after switching to L. The change in eGFR after the initiation of S was negatively correlated with the eGFR value at 1 year before switching.
CONCLUSIONS: The administration of S had an obvious effect on the systemic or renal hemodynamics in contrast to the fact that the administration of L had no effect on these parameters. It is thus important to use these agents with different excretion routes, properly taking the patients' renal function into account.

Entities:  

Keywords:  Blood pressure; Linagliptin; Sitagliptin; Type 2 diabetes; eGFR

Year:  2017        PMID: 30603346      PMCID: PMC6224920          DOI: 10.1007/s13340-017-0320-4

Source DB:  PubMed          Journal:  Diabetol Int        ISSN: 2190-1678


  11 in total

Review 1.  Tubuloglomerular feedback and the control of glomerular filtration rate.

Authors:  Volker Vallon
Journal:  News Physiol Sci       Date:  2003-08

2.  Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function.

Authors:  Giacomo Zoppini; Giovanni Targher; Michel Chonchol; Vittorio Ortalda; Carlo Negri; Vincenzo Stoico; Enzo Bonora
Journal:  Clin J Am Soc Nephrol       Date:  2012-01-26       Impact factor: 8.237

3.  The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes.

Authors:  Hajime Maeda; Akira Kubota; Yasushi Tanaka; Yasuo Terauchi; Ikuro Matsuba
Journal:  Diabetes Res Clin Pract       Date:  2011-11-03       Impact factor: 5.602

4.  Association of Na(+)-H(+) exchanger isoform NHE3 and dipeptidyl peptidase IV in the renal proximal tubule.

Authors:  A C Girardi; B C Degray; T Nagy; D Biemesderfer; P S Aronson
Journal:  J Biol Chem       Date:  2001-10-05       Impact factor: 5.157

5.  Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: the COMPASS randomized controlled trial.

Authors:  M Takihata; A Nakamura; K Tajima; T Inazumi; Y Komatsu; H Tamura; S Yamazaki; Y Kondo; M Yamada; M Kimura; Y Terauchi
Journal:  Diabetes Obes Metab       Date:  2013-01-24       Impact factor: 6.577

6.  Dipeptidyl peptidase IV inhibition downregulates Na+ - H+ exchanger NHE3 in rat renal proximal tubule.

Authors:  Adriana Castello Costa Girardi; Lívia Emy Fukuda; Luciana Venturini Rossoni; Gerhard Malnic; Nancy Amaral Rebouças
Journal:  Am J Physiol Renal Physiol       Date:  2007-12-12

7.  Renal hemodynamics in newly presenting non-insulin dependent diabetes mellitus.

Authors:  J P Vora; J Dolben; J D Dean; D Thomas; J D Williams; D R Owens; J R Peters
Journal:  Kidney Int       Date:  1992-04       Impact factor: 10.612

8.  Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: a streptozotocin-induced model using wild-type and DPP4-deficient rats.

Authors:  Yasushi Kirino; Youichi Sato; Takayuki Kamimoto; Kazuyoshi Kawazoe; Kazuo Minakuchi; Yutaka Nakahori
Journal:  J Endocrinol       Date:  2008-10-17       Impact factor: 4.286

9.  Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial.

Authors:  Anthony H Barnett; Holger Huisman; Russell Jones; Maximilian von Eynatten; Sanjay Patel; Hans-Juergen Woerle
Journal:  Lancet       Date:  2013-08-13       Impact factor: 79.321

10.  Pleiotropic effects of sitagliptin in the treatment of type 2 diabetes mellitus patients.

Authors:  Akira Kubota; Hajime Maeda; Akira Kanamori; Kiyokazu Matoba; Yasuyuki Jin; Fuyuki Minagawa; Mitsuo Obana; Koutarou Iemitsu; Shogo Ito; Hikaru Amemiya; Mizuki Kaneshiro; Masahiko Takai; Hideaki Kaneshige; Kazuhiko Hoshino; Masashi Ishikawa; Nobuaki Minami; Tetsuo Takuma; Nobuo Sasai; Sachio Aoyagi; Takehiro Kawata; Atsuko Mokubo; Hiroshi Takeda; Shin Honda; Hideo Machimura; Tetsuya Motomiya; Manabu Waseda; Yoshikazu Naka; Yasushi Tanaka; Yasuo Terauchi; Ikuro Matsuba
Journal:  J Clin Med Res       Date:  2012-09-12
View more
  1 in total

1.  Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study.

Authors:  Michael Fralick; Sarah K Chen; Elisabetta Patorno; Seoyoung C Kim
Journal:  Ann Intern Med       Date:  2020-01-14       Impact factor: 25.391

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.